Compare Nuwellis Inc (NUWE) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Teradyne, Inc. — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Teradyne, Inc. trades at $402.68 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 28336.4× Nuwellis Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Teradyne, Inc. for 37 Days on average.
| NUWE | TER | |
|---|---|---|
Market Cap | $2.20M | $62.34B |
Volume | 121,544 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $146.65 | $483.84 |
52-Week Low | $0.68 | $132.05 |
Typical Hold Time | 26 Days | 37 Days |
Enterprise Value | -$1.52M | $62.08B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Teradyne (TER) trades at $398.72, down 3.17% on the day, but maintains a bullish technical signal with strong analyst support. The stock shows robust fundamentals, including a 25.77% net income margin and consistent earnings beats, with Q3 2026 results pending. Recent news highlights expansion in AI-driven test equipment and strategic partnerships, positioning the company for growth in semiconductor and robotics markets.
The outlook for TER is positive, driven by AI and high-performance computing demand, with a consensus price target of $461.50 implying 16% upside. Risks include high valuation multiples and reliance on semiconductor cycle stability, but strong institutional interest and earnings momentum support a constructive view for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
